Abstract
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
Original language | English |
---|---|
Pages (from-to) | 512-519 |
Number of pages | 8 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 22 |
Issue number | 8 |
DOIs | |
State | Published - Oct 2024 |